|
US7094885B2
|
|
Skeletal-targeted radiation to treat bone-associated pathologies
|
|
US2003220233A1
|
|
Radiolabeled annexins
|
|
US2003143233A1
|
|
Streptavidin expressed gene fusions and methods of use thereof
|
|
US2003083733A1
|
|
Therapeutic inhibitor of vascular smooth muscle cells
|
|
US2003103948A1
|
|
Streptavidin expressed gene fusions and methods of use thereof
|
|
NZ518799A
|
|
Delivery vehicles for bioactive agents comprising oil in water
|
|
US2003129191A1
|
|
Pretargeting methods and compounds
|
|
CA2434302A1
|
|
Therapeutic and diagnostic compounds, compositions, and methods
|
|
US2002086896A1
|
|
Therapeutic inhibitor of vascular smooth muscle cells
|
|
USRE38008E
|
|
Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
|
|
US6491938B2
|
|
Therapeutic inhibitor of vascular smooth muscle cells
|
|
US6534037B1
|
|
Non-steroidal compounds for steroid receptors and uses relating thereto
|
|
WO0076556A2
|
|
High dose radionuclide complexes for bone marrow suppression
|
|
EP1190061A1
|
|
Streptavidin expressed gene fusions and methods of use thereof
|
|
US6416738B1
|
|
Pretargeting methods and compounds
|
|
EP1141011A2
|
|
Compounds and methods to inhibit or augment an inflammatory response
|
|
US6359111B1
|
|
Opioid receptor targeting
|
|
US6358490B2
|
|
Three-step pretargeting methods and compounds
|
|
WO9921533A2
|
|
Delivery vehicles for bioactive agents and uses thereof
|
|
US6251920B1
|
|
Prevention and treatment of cardiovascular pathologies
|
